A Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC

NCT02847377 | Completed

• 1 other identifier: IMK RUN 2
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The development of biomarkers will lead the dynamic of personalized medicine and fill the unsatisfied needs in oncology for prediction of therapeutic response. Molecular imaging enables non invasive quantification of biomarkers. The development of molecular imaging biomarkers is closely related to the development of therapeutic molecules. Among the potential targets, kinases offer a lot of advantages: (i) they play a central role in cellular regulation, (ii) numerous kinase-specific small molecule libraries exist in biotech and pharma industry, (iii) several kinase-targeted therapies are used in clinic (imatinib, sorafenib, sunitinib…) with application across a variety of therapeutic indications. Among the imaging technologies, the Positron Emission Tomography (PET) is the most sensitive and dedicated to evaluate small molecules. However few radiotracers are available and their specificity limits their clinical use. The IMAkinib® approach is an innovative method proposed to develop new PET radiotracers adapted to current medical and economical challenges. The epidermal growth factor receptor (EGFR) is an established target for the treatment of advanced non-small cell lung cancer (NSCLC). The EGFR tyrosine kinase inhibitors (TKIs) Gefitinib (Iressa®), erlotinib (Tarceva®) and afatinib (Giotrif®) have already been approved for treatment of NSCLC harboring EGFR activating mutations (L858R or del exon 19). Unfortunately the majority of patients will develop a resistance to the TKI in the long term (6-12 months). If the mechanism of resistance is not yet fully characterized, most patients (50%) will acquire an additional T790M mutation of EGFR. TKI PET-imaging can provide a tool to determine and predict responsiveness to EGFR TKI in vivo. That is why, the investigators have selected and radiolabeled (18-Fluor) a compound targeting specifically EGFR mutated (\[18F\]-ODS2004436) which was further evaluated in a preclinical imaging study to determine the feasibility of TKI-PET. The investigators proved in vivo that \[18F\]-ODS2004436 a compound is a good candidate to evaluate the EGFR activity in human lung tumours using PET imaging.

Conditions

Carcinoma, Non-Small-Cell Lung

Outcome Measures

Primary Outcomes (2)

• Evaluation of sensibility of [18F] ODS2004436

  Sensibility will be evaluated by positron emission tomography (PET) performed on EGFR mutant patient

  1 day

• Evaluation of specificity of [18F] ODS2004436

  Specificity will be evaluated by positron emission tomography (PET) performed on EGFR wild type patient

  1 day

Other Outcomes (1)

• Security

  10 days

Study Arms (1)

[18F]-ODS2004436

EXPERIMENTAL

Two TEP will be performed with the radiotracer \[18F\]-ODS2004436

Other: Injection of [18F]-ODS2004436 radiotracer

Interventions

Injection of [18F]-ODS2004436 radiotracer OTHER

[18F]-ODS2004436

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• more than 18 years,
• Willing and able to sign written informed consent,
• Histologically confirmed diagnosis of adenocarcinoma NSCLC:
• positive mutated KRas homogeneous population for EGFR Wild type (WT) patients (exclusive with EGFR mutation)
• EGFR activating mutation (All mutations: 719, 790, 861, 858 or del exon 19 and exon 20),
• Patient with EGFR mutation will be sensitive to TKI
• Treatment naïve patients,
• Performance status ≤ 2 on the Eastern Cooperative Oncology Group (ECOG) criteria,
• No concomitant prescriptions including cyclosporin A, valproic acid, phenobarbital, phenytoin, ketoconazole,
• Adequate hematologic (ANC count ≥ 1,500/uL, platelet count ≥ 100,000/mm3), hepatic (bilirubin level ≤ 1.5 mg/dL, Transaminase (AST/ALT) ≤ 80 IU/L), and renal (creatinine concentration ≤ 1.5 mg/dL) function,
• Patients with brain metastasis are allowed unless there were clinically significant neurological symptoms or signs.

You may not qualify if:

• Known severe hypersensitivity to Gefitinib or Afatinib or any of the tablet excipients,
• Inability to swallow tablets,
• Other coexisting malignant disease,
• Concomitant use of phenytoin, carbamazepine, rifampicin, barbiturates, or St John's wort; severe or uncontrolled systemic disease; clinically active interstitial lung disease (except uncomplicated lymphangitic carcinomatosis),
• Female subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control,
• Subjects under guardianship, curators or judicial protection

Sponsors & Collaborators

• Centre Georges Francois Leclerc: lead

Study Sites (1)

CGFL

Dijon, 21079, France

Location

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Pierre FUMOLEAU, Pr

  Centre Georges Francois Leclerc

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 12, 2016
• First Posted: July 28, 2016
• Study Start: September 27, 2016
• Primary Completion: September 27, 2016
• Study Completion: March 19, 2019
• Last Updated: January 27, 2020

Record last verified: 2019-11

Locations

FR (1)